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Return of chloroquine antimalarial 
efficacy in Malawi
Malaria continues to be a leading killer of the world’s poorest 
children. Six decades after chloroquine was widely used in a 
global programme to eradicate malaria, Plasmodium falciparum 
continues to plague sub-Saharan Africa.
In 1993 Malawi was the first country in Africa to replace 
chloroquine with the combination of sulfadoxine and 
pyrimethamine for the treatment of malaria. At the time, 
the clinical efficacy of chloroquine was less than 50%. Since 
then, sulfadoxine-pyrimethamine has been the only available 
treatment for uncomplicated malaria in government health 
facilities.
Chloroquine resistance first emerged in South-east Asia and 
South America in the late 1950s and by the late 1970s it had 
made its way across to Africa, where it contributed to increased 
transmission of malaria and deaths.
According to the authors of this paper in the New England 
Journal of Medicine it has been suggested that reducing the use 
of chloroquine could result in the re-emergence of chloroquine-
sensitive P. falciparum, allowing this safe and affordable drug to 
be reintroduced. Although studies in Asia and West Africa have 
shown that the growth of the parasite in vitro was inhibited 
after chloroquine use was reduced, a return to clinical efficacy 
has not yet been demonstrated.
Resistance in chloroquine-resistant falciparum malaria 
is associated with a point mutation in the P. falciparum 
chloroquine-resistance transporter gene. The authors of this 
paper previously measured the prevalence of this molecular 
marker in Blantyre, Malawi, before, during and after the 
withdrawal of chloroquine from use. From 1992 to 2000, the 
prevalence of the marker gradually decreased, disappearing 
completely by 2001. However, in neighbouring countries, 
where chloroquine continued to be used, more than 90% of 
P. falciparum infections were caused by chloroquine-resistant 
parasites.
A randomised clinical trial involving 210 children with 
uncomplicated P. falciparum malaria in Blantyre was carried 
out. The children were treated with either chloroquine or 
sulfadoxine-pyrimethamine and followed up for 28 days to 
assess how clinically effective the drug was. They found that 
treatment failure occurred in 1 of 80 participants assigned to 
chloroquine, compared with 71 of 87 participants assigned to 
sulfadoxine-pyrimethamine. 
It would appear that chloroquine, a safe and inexpensive 
treatment for malaria, is once again highly effective in Malawi, 
12 years after it was withdrawn from use because of high rates 
of treatment failure. What is more, infection and fever cleared 
more quickly in the chloroquine group than in the sulfadoxine-
pyrimethamine group. Chloroquine was not entirely absent 
in Malawi. The drug was available over the counter and used 
mainly by travellers as prophylaxis and by adult Malawians 
to self-treat symptoms of malaria. So complete elimination 
of chloroquine use appears not to be necessary to allow the 
survival advantage enjoyed by chloroquine-resistant parasites 
to be lost when the drug is largely absent.
The authors suggest that the introduction of combination 
antimalarial therapies elsewhere in Africa and the reduction 
in chloroquine use may result in a resurgence of chloroquine-
susceptible falciparum malaria throughout the region. They 
recommend that chloroquine should be completely withdrawn 
from use where its clinical efficacy is already impaired. To 
prevent the re-emergence of resistance, chloroquine should be 
reintroduced in combination with other drugs.
Laufer M, et al. NEJM  2006;  355: 1959-1966.
Screening for chronic kidney disease
Current guidelines in most parts of the world advocate 
screening for chronic kidney disease only in those with 
hypertension or diabetes. However, more widespread 
screening of the general population has been proposed; in the 
developed world everyone who goes to the GP. However, these 
recommendations are based on consensus procedures and the 
different screening strategies have not been compared for their 
ability to detect chronic kidney disease. Another assumption 
is that anyone with advanced renal disease (stages 3 - 5) will 
require kidney replacement, but the natural course of the 
disease in those with newly detected renal insufficiency is not 
well described.
The authors of this paper in the British Medical Journal set out 
to find an effective screening strategy for detecting patients 
with chronic kidney disease and to describe the natural 
course of the disease. The study took place in Norway, using 
participants in a large-scale general health survey between 1995 
and 1997. Participants were 65 604 people aged over 20, who 
comprised slightly more than 70% of the adults aged over 20 
in that particular county of Norway. They looked at end-stage 
renal disease (ESRD) and cardiovascular mortality.
They found that 3 069 people out of the 65 604 had chronic 
kidney disease (estimated glomerular filtration rate less 
than 60 ml/min/1.73 m2). This meant that to find one case 
of chronic kidney disease they would need to screen 20.6 
people. Restricting screening to those aged over 55 or with 
hypertension or diabetes would identify 93% of patients with 
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chronic kidney disease and need only 8.7 people screened 
to identify one case. Screening only people with known 
hypertension or diabetes detected 44.2% of all cases and needed 
6 people screened to identify one case. During the 8 years of 
follow-up in this study only 38 of the 3 069 people with chronic 
kidney disease progressed to ESRD. The risk of progression 
was particularly low in those without hypertension or diabetes, 
women and those aged at least 70 with a glomerular filtration 
rate of 45 - 49 ml/min/1.73 m2. However, in contrast, there was 
high cardiovascular mortality: 3.5, 7.4 and 10.1 deaths per 100 
person-years among people with a glomerular filtration rate of 
45 - 49, 30 - 44 and less than 30 ml/min/1.73 m2 respectively.
The authors concluded that screening people with 
hypertension, diabetes and age over 55 was the most effective 
strategy to detect patients with chronic kidney disease. 
However, the risk of end-stage renal failure among those 
detected was low.
Hallan SI, et al. BMJ 2006; 333: 1047-1050.
The human face of epilepsy
There are 40 million people worldwide who suffer from 
epilepsy. Around 80% of them live in the developing world 
where resources for care are extremely limited. There are 
qualitative and anecdotal reports that people in Africa 
who suffer from epilepsy are disadvantaged socially and 
economically, but there are few quantitative data available. 
The authors of this recent study in the Lancet Neurology 
did a cross-sectional study of people with epilepsy who were 
matched with people with a non-stigmatised chronic medical 
condition and living in Zambia. Participants were verbally 
questioned to determine their demographic characteristics, 
education, employment status, housing and environmental 
quality, food security, health care use, personal safety and 
perceived stigma. 
They found that people with epilepsy were stigmatised, less 
likely to be employed and, if employed, in poor employment 
and had less education. Their housing was likely to be of 
poor quality; they had little access to water and were unlikely 
to have electricity in their home. They also had greater food 
insecurity than the control group. During pregnancy, women 
with epilepsy were more likely to deliver at home than in a 
hospital or clinic. The personal safety of people with epilepsy 
was also a problem. Rape rates among women with epilepsy 
were 20% compared with 3% in the control group.
The conclusion is that epilepsy places yet another burden on 
lives already far from ideal.
Birbeck G, et al. Lancet Neurology 2006; DOI:10.1016/S1474-4422(06)70629-9a.
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